Clonidine hydrochloride - Hypertension
You are here : Home > Formulary Search > Clonidine hydrochloride - Hypertension
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Blue
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Initiation and stabilisation by the specialist before transfer of prescribing to GP.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Clonidine hydrochloride
Indication :
Hypertension
Group Name :
Keywords :
severe hypertension, resistant hypertension
Brand Names Include :
Important Information :
Reserved for severe / resistant hypertension.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Other Indications
Below are listed other indications that Clonidine hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Hypertension.
- Aliskiren
- Amlodipine
- Atenolol
- Azilsartan medoxomil
- Bendroflumethiazide
- Bisoprolol fumarate
- Candesartan cilexetil
- Captopril
- Carvedilol
- Celiprolol hydrochloride
- Chlortalidone
- Co-tenidone (Atenolol/chlortalidone)
- Diltiazem hydrochloride
- Doxazosin mesilate
- Enalapril maleate
- Eprosartan
- Hydralazine hydrochloride
- Indapamide
- Irbesartan
- Irbesartan / Hydrochlorothiazide
- Lercanidipine hydrochloride
- Lisinopril
- Lisinopril / Hydrochlorothiazide
- Losartan potassium
- Metolazone
- Metoprolol tartrate
- Moxonidine
- Nebivolol
- Nicardipine hydrochloride
- Nifedipine
- Olmesartan medoxomil
- Perindopril arginine
- Perindopril erbumine
- Prazosin hydrochloride
- Propranolol hydrochloride
- Quinapril hydrochloride
- Ramipril
- Spironolactone
- Telmisartan
- Valsartan
- Valsartan with hydrochlorothiazide
Committee Recommendations (1)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.